We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+199.34%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$404M
AUM Growth
+$265M
Cap. Flow
+$92M
Cap. Flow %
22.79%
Top 10 Hldgs %
66.28%
Holding
52
New
21
Increased
12
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$11.7M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.58M
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$7.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.11M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.05M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$6.16M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$5.49M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.03M
4
VCYT icon
Veracyte
VCYT
+$2.7M
5
ARGX icon
argenx
ARGX
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 83.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARX
51
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-55,000
Closed -$1.3M
CEMI
52
DELISTED
Chembio diagnostics, Inc.
CEMI
– –
-41,667
Closed -$255K
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Acuta Capital Partners held 52 positions worth $404M, up 191% from $139M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Acuta Capital Partners deployed $92M of net new capital in Q4 2019, opening 21 new positions and adding to 12 existing holdings. Its largest new stake was Adverum Biotechnologies: 132,250 shares worth $15.2M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $6.16M trimmed.

  • Acuta Capital Partners's largest Q4 2019 buy was Adverum Biotechnologies: 132,250 shares worth $15.2M.
  • Acuta Capital Partners added most to Karyopharm Therapeutics in Q4 2019, an estimated $5.1M increase.
  • Acuta Capital Partners's biggest Q4 2019 reduction was Arvinas, cutting an estimated $6.16M.
  • Acuta Capital Partners fully exited CRISPR Therapeutics in Q4 2019, selling an estimated $5.49M.
  • Acuta Capital Partners's ten largest holdings make up 66% of its $404M portfolio in Q4 2019.
  • Acuta Capital Partners opened 21 new positions and closed 14 in Q4 2019.
  • Acuta Capital Partners's portfolio value rose 191% quarter-over-quarter to $404M.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.